Document is current
Any future updates will be listed below
-
Authors
Ji, Xin
Wang, Lizhen
Zhong, Yudan
Xu, Qian
Yan, Junjie
Pan, Donghui
Xu, Yuping
Chen, Chongyang
Wang, Jing
Wang, Guangji
Yang, Min
Li, Tiannv
Tang, Lijun
Wang, Xinyu https://orcid.org/0000-0002-9167-2077
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (32371434)
- License Information
-
More Information
Article History
Received: 6 July 2024
Accepted: 22 November 2024
First Online: 28 November 2024
Declarations
:
: All applicable international, national, and/or institutional guidelines for the care and welfare of animals were followed. All animal procedures were conducted under a protocol approved by the Institutional Animal Care and Ethics Committee of Jiangsu Institute of Nuclear Medicine (Wuxi, China) (Title of the approved project, Mesenchymal stem cell regulation and PET imaging cell tracking. Approval number, JSINM-2023-100. Date of approval, 2023.7.28.). Human umbilical cord mesenchymal stem cells (hUC-MSCs) were obtained from Nanjing Drum Tower Hospital (Nanjing, China) and manufactured by Jiangsu Renocell Biotech Co., Ltd. (Nanjing, China). It was approved by ethics committee of Nanjing Drum Tower Hospital (Nanjing, China). The ethics approval number is 2020-197-01. Date of approval is 2020.07.06. The cell product has been certified by the National Institutes for Food and Drug Control of China.
: All authors confirm their consent for publication.
: All authors except author Jing Wang report no conflict of interest. Author Jing Wang is a deputy director in Jiangsu Renocell Biotech Co., Ltd.
: The authors declare that artificial intelligence was not used in this study.
